DE602004008889D1 - Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs - Google Patents

Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs

Info

Publication number
DE602004008889D1
DE602004008889D1 DE602004008889T DE602004008889T DE602004008889D1 DE 602004008889 D1 DE602004008889 D1 DE 602004008889D1 DE 602004008889 T DE602004008889 T DE 602004008889T DE 602004008889 T DE602004008889 T DE 602004008889T DE 602004008889 D1 DE602004008889 D1 DE 602004008889D1
Authority
DE
Germany
Prior art keywords
mif
inhibitory factor
prostata
krebs
macrophage migration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004008889T
Other languages
English (en)
Other versions
DE602004008889T2 (de
Inventor
Katherine Meyer Siegler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Veterans Affairs VA
Original Assignee
US Department of Veterans Affairs VA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Veterans Affairs VA filed Critical US Department of Veterans Affairs VA
Publication of DE602004008889D1 publication Critical patent/DE602004008889D1/de
Application granted granted Critical
Publication of DE602004008889T2 publication Critical patent/DE602004008889T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE602004008889T 2003-02-24 2004-02-24 Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs Expired - Fee Related DE602004008889T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44889403P 2003-02-24 2003-02-24
US448894P 2003-02-24
US644797 2003-12-17
US10/644,797 US7361474B2 (en) 2003-02-24 2003-12-17 Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer
PCT/US2004/005288 WO2004076679A2 (en) 2003-02-24 2004-02-24 Serum macrophage migration inhibitory factor (mif) as marker for prostate cancer

Publications (2)

Publication Number Publication Date
DE602004008889D1 true DE602004008889D1 (en) 2007-10-25
DE602004008889T2 DE602004008889T2 (de) 2008-06-12

Family

ID=32912312

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004008889T Expired - Fee Related DE602004008889T2 (de) 2003-02-24 2004-02-24 Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs

Country Status (7)

Country Link
US (1) US7361474B2 (de)
EP (1) EP1601968B1 (de)
AT (1) ATE373239T1 (de)
AU (1) AU2004214971A1 (de)
CA (1) CA2517076A1 (de)
DE (1) DE602004008889T2 (de)
WO (1) WO2004076679A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008063046A1 (de) 2008-12-23 2010-06-24 Justus-Liebig-Universität Giessen Medizinische Verwendung des ribosomalen Protein S19 (RPS19)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
US7897349B2 (en) * 2003-12-30 2011-03-01 The United States Of America As Represented By The Department Of Veterans Affairs Macrophage migration inhibitory factor (MIF) as marker for urological inflammatory disease
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
US20060105405A1 (en) * 2004-10-20 2006-05-18 Onco Detectors International, Llc Migration inhibitory factor in serum as a tumor marker for prostate, bladder, breast, ovarian, kidney, pancreatic and lung cancer and for diagnosis of endometriosis
EP1805513A4 (de) * 2004-10-20 2009-06-10 Onco Detectors International L Migrationshemmfaktorim serum als tumormarker für prostata-, blasen-, brust-, ovarial-, nieren-und lungenkarzinom
CA2600175A1 (en) 2005-03-24 2006-03-20 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
WO2006127609A2 (en) * 2005-05-23 2006-11-30 The United States Of America As Represented By The Department Of Veterans Affairs Polymorphism in the macrophage migration inhibitory factor (mif) gene as marker for prostate cancer
WO2007044566A2 (en) * 2005-10-07 2007-04-19 Baylor Research Institute Diagnosis of systemic onset juvenile idiopathic arthritis through blood leukocyte microarray analysis
CA2636855C (en) 2006-01-11 2016-09-27 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP3031918B1 (de) 2006-05-11 2018-03-14 Raindance Technologies Inc. Mikrofluidische vorrichtungen
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
US8614057B2 (en) * 2008-06-12 2013-12-24 The Invention Science Fund I, Llc Methods for collecting and detecting oligonucleotides
US8252528B2 (en) * 2008-06-12 2012-08-28 The Invention Science Fund I, Llc Methods, compositions, and kits for collecting and detecting oligonucleotides
US8252529B2 (en) * 2008-06-12 2012-08-28 The Invention Science Fund I, Llc Methods for collecting and detecting oligonucleotides
JP5539980B2 (ja) * 2008-07-10 2014-07-02 スリーエム イノベイティブ プロパティズ カンパニー 粘弾性光ガイドを有する再帰反射物品及び装置
CN102138086B (zh) 2008-07-10 2014-11-26 3M创新有限公司 具有粘弹性光导的回射制品和装置
CN102124384B (zh) 2008-07-10 2016-10-12 3M创新有限公司 粘弹性光导
EP2315629B1 (de) 2008-07-18 2021-12-15 Bio-Rad Laboratories, Inc. Tröpfchenbibliotheken
KR20110043732A (ko) 2008-08-08 2011-04-27 쓰리엠 이노베이티브 프로퍼티즈 컴파니 광을 처리하기 위한 점탄성층을 갖는 도광체
WO2010111231A1 (en) 2009-03-23 2010-09-30 Raindance Technologies, Inc. Manipulation of microfluidic droplets
US9464179B2 (en) 2009-04-15 2016-10-11 3M Innovative Properties Company Process and apparatus for a nanovoided article
TWI491930B (zh) 2009-04-15 2015-07-11 ３Ｍ新設資產公司 光學膜
WO2010120468A1 (en) 2009-04-15 2010-10-21 3M Innovative Properties Company Process and apparatus for a nanovoided article
JP5840126B2 (ja) 2009-06-25 2016-01-06 スリーエム イノベイティブ プロパティズ カンパニー 光活性化抗微生物性物品及び使用方法
JP2012532103A (ja) 2009-06-30 2012-12-13 スリーエム イノベイティブ プロパティズ カンパニー 光活性化抗菌性物品及び使用方法
CN102625677B (zh) 2009-08-21 2016-05-18 3M创新有限公司 使用吸水性应力分布材料来减轻组织创伤的方法和产品
WO2011022525A1 (en) 2009-08-21 2011-02-24 3M Innovative Properties Company Methods and products for illuminating tissue
JP5775078B2 (ja) 2009-08-21 2015-09-09 スリーエム イノベイティブ プロパティズ カンパニー 耐水性応力分散材料を用いる、組織損傷を低減するための方法及び製品
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
EP2517025B1 (de) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Verfahren zur reduzierung des austauschs von molekülen zwischen tröpfchen
WO2011088161A1 (en) 2010-01-13 2011-07-21 3M Innovative Properties Company Optical films with microstructured low refractive index nanovoided layers and methods therefor
WO2011100277A1 (en) 2010-02-10 2011-08-18 3M Innovative Properties Company Illumination device having viscoelastic layer
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
CA2789425C (en) 2010-02-12 2020-04-28 Raindance Technologies, Inc. Digital analyte analysis with polymerase error correction
US9562897B2 (en) 2010-09-30 2017-02-07 Raindance Technologies, Inc. Sandwich assays in droplets
EP2628035A1 (de) 2010-10-11 2013-08-21 3M Innovative Properties Company Beleuchtungsvorrichtung mit einem viskoelastischen lichtleiter
US9995861B2 (en) 2010-10-20 2018-06-12 3M Innovative Properties Company Wide band semi-specular mirror film incorporating nanovoided polymeric layer
EP2646860A1 (de) 2010-12-04 2013-10-09 3M Innovative Properties Company Beleuchtungsanordnung und herstellungsverfahren dafür
EP2646861A2 (de) 2010-12-04 2013-10-09 3M Innovative Properties Company Beleuchtungsanordnung und herstellungsverfahren dafür
EP2673614B1 (de) 2011-02-11 2018-08-01 Raindance Technologies, Inc. Verfahren zur bildung gemischter tröpfchen
US9150852B2 (en) 2011-02-18 2015-10-06 Raindance Technologies, Inc. Compositions and methods for molecular labeling
CN103597379B (zh) 2011-05-25 2016-10-05 3M创新有限公司 光控膜
EP2714970B1 (de) 2011-06-02 2017-04-19 Raindance Technologies, Inc. Enzymquantifizierung
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013120089A1 (en) 2012-02-10 2013-08-15 Raindance Technologies, Inc. Molecular diagnostic screening assay
EP3524693A1 (de) 2012-04-30 2019-08-14 Raindance Technologies, Inc. Digitale analytanalyse
WO2014172288A2 (en) 2013-04-19 2014-10-23 Raindance Technologies, Inc. Digital analyte analysis
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
US9904001B2 (en) 2014-03-18 2018-02-27 3M Innovative Properties Company Marketing strip with viscoelastic lightguide
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3789413T2 (de) * 1986-10-03 1994-07-28 Ciba Geigy Ag Lymphokin-ähnliche Peptide.
US5250297A (en) 1989-10-20 1993-10-05 Hybritech Incorporated Tumor-associated antigen, antibodies, compositions and uses therefor
US5614372A (en) 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
US5654161A (en) 1995-05-12 1997-08-05 Chiron Diagnostics Corporation Method for diagnosing prostate cancer
US6420188B1 (en) 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
US6043044A (en) 1997-07-15 2000-03-28 Hudson; Perry B. Macrophage migration inhibitory factor as diagnostic and prognostic marker for metastatic adenocarcinoma
US6268151B1 (en) 2000-01-20 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of macrophage migration inhibitory factor expression
US20030235584A1 (en) * 2000-02-28 2003-12-25 Kloetzer William S. Method for preparing anti-MIF antibodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008063046A1 (de) 2008-12-23 2010-06-24 Justus-Liebig-Universität Giessen Medizinische Verwendung des ribosomalen Protein S19 (RPS19)

Also Published As

Publication number Publication date
WO2004076679A3 (en) 2004-10-28
CA2517076A1 (en) 2004-09-10
EP1601968B1 (de) 2007-09-12
US7361474B2 (en) 2008-04-22
US20040171021A1 (en) 2004-09-02
ATE373239T1 (de) 2007-09-15
WO2004076679A2 (en) 2004-09-10
EP1601968A2 (de) 2005-12-07
AU2004214971A1 (en) 2004-09-10
DE602004008889T2 (de) 2008-06-12

Similar Documents

Publication Publication Date Title
DE602004008889D1 (en) Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs
Liu et al. Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers
Elsheikh et al. Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype
Janz et al. Y‐box factor YB‐1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI‐1
ES2355388T3 (es) Métodos para la detección precoz de cáncer.
Rainczuk et al. Evidence for the antagonistic form of CXC‐motif chemokine CXCL10 in serous epithelial ovarian tumours
ATE457362T1 (de) Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs
WO2006036788A3 (en) Methods and compositions for evaluating breast cancer prognosis
Tunuguntla et al. Diagnostic and prognostic molecular markers in renal cell carcinoma
Lee et al. High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients
O'Brien et al. The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro
DE602006020544D1 (de) Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs
ES2538362T3 (es) Clasificación, estadificación y pronóstico del cáncer mediante el uso de osteopontina-C
WO2006055880A3 (en) Diagnostic pkm2 methods and compositions
MX2009008307A (es) Metodos y materiales para identificar el origen de un carcinoma de origen primario desconocido.
JP2015505370A5 (de)
Ouyang et al. α-Methylacyl-CoA racemase spliced variants and their expression in normal and malignant prostate tissues
JP2010535014A5 (de)
Buhl et al. CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia
Zhao et al. RhoC, vascular endothelial growth factor and microvascular density in esophageal squamous cell carcinoma
Uyen et al. Aberrant methylation of protocadherin 17 and its prognostic value in pediatric acute lymphoblastic leukemia
BRPI0618450A2 (pt) método, bem como uso de pelo menos um polimorfismo, para a determinação e avaliação do risco de um sujeito desenvolver sìdrome coronariana aguda, sondas e/ou iniciadores nucleotìdicos, microarranjo de ácidos nucléicos e de anticorpos, método para a triagem de compostos, bem como para avaliação de possìvel sensibilidade de um sujeito, kit e uso de um agente capaz de modular a atividade de mmp12
Araz et al. Are preoperative serum CA15-3 levels different in breast cancer subgroups?
Ilijazi et al. Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer
TSEDEN‐ISH et al. Disease‐free survival of patients after surgical resection of non‐small cell lung carcinoma and correlation with excision repair cross‐complementation group 1 expression and genotype

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted
8339 Ceased/non-payment of the annual fee